Endocrine Journal
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
ORIGINALS
Effect of Colestimide Therapy for Glycemic Control in Type 2 Diabetes Mellitus with Hypercholesterolemia
Tadashi YAMAKAWATatsuro TAKANOHirotoshi UTSUNOMIYAKazuaki KADONOSONOAtushi OKAMURA
Author information
JOURNALS FREE ACCESS

2007 Volume 54 Issue 1 Pages 53-58

Details
Abstract

Colestimide is a new anion-exchange resin used to lower serum cholesterol in Japan. Because of its excellent compliance, colestimide can replace cholestyramine. To clarify the effect of colestimide on glycemic controls, colestimide (3 g/day) or pravastatin (10 mg) was given orally to patients with type 2 diabetes treated with oral hypoglycemic agents or insulin who had low-density lipoprotein (LDL) cholesterol levels exceeding 3.6 mmol/l. In the colestimide groups, fasting plasma glucose concentrations had decreased significantly from 8.5 ± 1.4 to 7.7 ± 1.5 mmol/l at 3 months (P<0.05), as had glycated hemoglobin (HbA1c) from 7.7 ± 0.7% to 6.8 ± 0.5%, for an 8% reduction (P<0.01). Fasting plasma glucose and HbA1c did not change in the pravastatin group. Total cholesterol and LDL-cholesterol decreased significantly (P<0.01) with either medication, with similar reduction rates for both drugs. Doses of oral hypoglycemic agents and insulin did not change during the study, and body weight remained stable. Considering that patients with type 2 diabetes often have hyperlipidemia, colestimide therapy may have a clinically useful dual action in such patients.

Information related to the author
© The Japan Endocrine Society
Previous article Next article
feedback
Top